Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aastrom Biosciences Inc Announces Management Change-Form 8-K

Wednesday, 12 Dec 2012 10:04pm EST 

Aastrom Biosciences Inc reported in its Form 8-K that effective as of December 14, 2012, Daniel Orlando will assume the position of interim Chief Executive Officer (CEO) and President of Aastrom Biosciences, Inc. (Company) and Tim M. Mayleben, who announced his retirement in October 2012, will step down from his role as the Chief Executive Officer and President. Mr. Mayleben will continue as a member of the Board of Directors and will continue to be available as a consultant to assist with management transition issues. 

Company Quote

0.06 +1.54%
27 Aug 2014